Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: biosimilars

Year in Review: The ACR Advances Education, Rheumatic Disease Awareness, Strategic Planning in 2017

Sharad Lakhanpal, MBBS, MD  |  November 5, 2017

It seems like yesterday I was asked to write my first presidential column, and here I am penning my last. It’s incredible how fast the time goes and yet how much gets done. That progress is made possible by the dedicated and talented group of ACR volunteers and staff. This year, the College has had…

Filed under:Patient PerspectiveResearch RheumWorkforce Tagged with:AC&RAffordable Care Act (ACA)American College of Rheumatology (ACR)AwarenessCDCCommittee on Rheumatologic Care (CORC)DatabasedrugEducationFDAgoalmissionResearchRheumatic DiseaserheumatologistRISETraining

Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

Angus Worthing, MD, FACP, FACR  |  October 19, 2017

Greetings, advocates! Here’s a brief, interim hodgepodge of updates to keep you posted on government advocacy before the deluge of information swamps you in San Diego. The Next Big Thing: Part B Drug Reimbursements Medicare currently plans to adjust reimbursement of doctors in the MIPS program in 2019, not only based on E/M office services,…

Filed under:Legislation & Advocacy Tagged with:cost-sharing reductionexecutive orderFDA-approved rheumatology biosimilarsMedicare payment adjustment planMIPSPart B drugsreduced insurance restrictionsWashington D.C. update

Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

Vanessa Caceres  |  October 17, 2017

As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

Filed under:Biologics/DMARDsDrug Updates Tagged with:AC&Radverse eventsAmerican College of Rheumatology (ACR)BiosimilarsBiosimilars in the EUdrugefficacyEuropeEuropean UnionfindingsinterchangeabilityMedicationoutcomepatient carepricingreportRheumatic DiseaserheumatologistsrheumatologySafetyTreatment

Pfizer Files Suit Against J and J over Remicade Contracts

Caroline Humer  |  September 20, 2017

(Reuters)—Drugmaker Pfizer Inc on Wednesday filed a lawsuit against Johnson and Johnson, saying its rival’s contracts with health insurers for blockbuster rheumatoid arthritis drug, Remicade, were anticompetitive and blocked sales of Pfizer’s new biosimilar. Pfizer said in the suit that Johnson and Johnson is offering discounts on its Remicade treatment in exchange for essentially excluding…

Filed under:Legal Updates Tagged with:Johnson and JohnsonlawsuitPfizer Inc.REMICADE (infliximab)

ARHP Stands Up for Members and Patients

Jan Stevens, BA, & Afton L. Hassett, PsyD  |  September 17, 2017

Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. ARHP volunteers are actively involved in the ACR’s efforts to advocate for the care of our patients and the rheumatology professionals who…

Filed under:Interprofessional PerspectiveLegislation & Advocacy Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)health professionalsLegislationmemberspatient carerheumatologyRheumPAC

RheumPAC: Answers to FAQs

From the College  |  September 17, 2017

What is RheumPAC? RheumPAC is the ACR’s nonpartisan political action committee (PAC) that works to elect and support pro-rheumatology candidates. It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created 10 years ago with the mission of educating, electing and supporting federal lawmakers who understand and can positively address…

Filed under:From the CollegeLegislation & Advocacy Tagged with:AC&RAdvocacyAmerican College of Rheumatology (ACR)Association of Rheumatology Professionals (ARP)CongressFAQLegislationpolitical action committeerheumatologyRheumPAC

FDA Approves First Biosimilar for the Treatment of Cancer

The U.S. Food and Drug Administration  |  September 14, 2017

Mvasi, a biosimilar to the cancer drug Avastin, is approved for certain colorectal, lung, brain, kidney and cervical cancers The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the treatment…

Filed under:Biologics/DMARDs Tagged with:Avastin (bevacizumab)biosimilar cancer drugCancerMvasi (bevacizumab-awwb)U.S. Food and Drug Administration

N.Y. Rheumatologist Makes Advocacy a Priority

Kelly Tyrrell  |  August 16, 2017

In 2005, not long after he became a private practice rheumatologist on Long Island, N.Y., Howard Blumstein, MD, dipped his toe into the advocacy pool at the encouragement of his partner, Max Hamburger, MD. “I thought it would be interesting to learn more about the issues that affect our patients and our practices, and I…

Filed under:Legislation & AdvocacyProfiles Tagged with:ACR’s Affiliate Society CouncilHoward BlumsteinNew York rheumatologist

Investments in Legislative Advocacy Pay Off for Ohio Association of Rheumatology

Gretchen Henkel  |  August 14, 2017

Like many other state rheumatology associations, the Ohio Association of Rheumatology (OAR) has recently been actively advocating for patient care at the state legislative level. The most recent example of OAR’s efforts included an Advocacy Day on May 4, when members met with state legislators to discuss topics of interest. It was the fourth such…

Filed under:Legislation & Advocacy Tagged with:Ohio Association of Rheumatology (OAR)step therapy

RISE Registry Data Now Available for Research Purposes

Sharad Lakhanpal, MBBS, MD  |  August 13, 2017

As medical professionals, we under­stand the impact quality research can have on how we care for our patients. The extensive adoption of electronic health records (EHRs) has enabled the collection of big data in rheumatology. This has provided a new and unique opportunity for the rheumatology community to conduct in-depth research into how patients are…

Filed under:EMRsPresident's PerspectiveTechnology Tagged with:datapatient carePractice ManagementrheumatologistrheumatologyRheumatology Informatics System for Effectiveness Registry

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences